Previous Article | Next Article 
Journal of Virology, May 2001, p. 4641-4648, Vol. 75, No. 10
0022-538X/01/$04.00+0 DOI: 10.1128/JVI.75.10.4641-4648.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
Locus Control Region of the Human CD2
Gene in a Lentivirus Vector Confers Position-Independent
Transgene Expression
Claudia M.
Kowolik,
Jun
Hu, and
Jiing-Kuan
Yee*
Department of Virology, Beckman Research
Institute, City of Hope, Duarte, California
Received 28 November 2000/Accepted 9 February 2001
 |
ABSTRACT |
Vectors derived from murine leukemia virus (MLV) have been used in
many human gene therapy clinical trials. However, insertion of the
locus control regions (LCRs) derived from the
-globin gene locus or
the CD2 gene into MLV vectors frequently led to vector
rearrangement. Since the human immunodeficiency virus (HIV) sequence
diverges significantly from the MLV sequence, we tested whether the LCR
sequence is more stable in the context of an HIV vector. Clones derived
from human fibrosarcoma line HT1080 cells transduced with an HIV vector
containing the T-cell-specific CD2 LCR exhibit the same wide range of
transgene expression as clones lacking the LCR. In contrast, Jurkat and
primary T-cell clones derived from the transduction of the
LCR-containing vector show, on average, a three- to fourfold increase
in transgene expression relative to that of the control vector. This is
consistent with previous observations that the CD2 LCR contains a
T-cell-specific enhancer. In addition, the clones derived from the
LCR-containing vector have a much lower clonal variation in transgene
expression than those derived from the control vector. We also
demonstrate that the level of transgene expression is proportional to
the vector copy number. These results suggest that the human CD2 LCR sequence is compatible with HIV vector sequences and confers enhanced integration site-independent and copy number-dependent expression of
the transgene. Thus, HIV vectors may represent the ideal vehicle to
deliver genes controlled by various cis-acting elements
such as LCRs.
 |
INTRODUCTION |
Murine leukemia virus (MLV)-derived
vectors have been widely used to introduce genes into mammalian cells
(12, 34). Since MLV integrates randomly into the host
genome, transgene expression is frequently influenced by the
surrounding host chromatin (20). A large portion of MLV
insertions has led to silencing or position effect variegation of gene
expression either immediately after insertion or following cell
expansion in culture or in vivo (11, 40, 45, 50-52). This
observation poses a major obstacle for the use of retrovirus vectors in
the treatment of human diseases. However, the discovery of the locus
control regions (LCRs) raises the possibility that the problem
associated with chromosomal position effects may be overcome: LCRs are
cis-regulatory elements that confer high-level,
tissue-specific expression of homologous and heterologous genes in a
position-independent, copy number-dependent manner (9, 18, 19,
46). In transgenic mice studies, LCRs have been shown to both
enhance transgene expression and direct integration site-independent
expression in various cell types (1, 9, 10, 19, 22, 44).
These observations led to the hope that incorporation of the LCR
sequence may overcome the position effect of the integration sites on
transgene expression from a retroviral vector.
However, insertion of the LCR from either the human CD2
(hCD2) or the
-globin gene into an MLV vector resulted in
frequent rearrangement of the vector sequences and low vector titers
from the producer cells. In the case of the
-globin gene, combining LCR derivatives containing only the nuclease hypersensitivity sites
with the deletion of intronic segments and/or various point mutations
in the gene led to increased vector titers and more stable proviral
genomes (25, 29, 31, 42, 43, 48). However, gene silencing
or position effect variegation continued to be observed in mice grafted
with the transduced hematopoietic stem cells (HSC). These results
suggest that sequences outside the nuclease hypersensitivity sites may
be required for position-independent expression of the transgene. In
the case of the hCD2 LCR, the vectors containing the LCR either were
prone to rearrange or failed to express higher levels of the transgene
compared with control vectors without the LCR (25). Thus,
sequences within the LCR may be incompatible with sequences in the MLV vectors.
Human immunodeficiency virus type 1 (HIV-1)-based vectors have recently
been demonstrated to efficiently deliver genes into mammalian cells.
Unlike MLV vectors, HIV-1 vectors are capable of transducing
nondividing cells both in culture and in vivo (5, 6, 8, 15, 24,
35, 38, 47). Compared with MLV, the HIV-1 sequence is
significantly different. The observations that some of the
cis-regulatory sequences inserted into HIV vectors are more
stable than those in MLV vectors and that a tissue-specific promoter
functions properly in the context of an HIV vector prompted us to
investigate the stability and function of the hCD2 LCR in an HIV-1
vector (24, 36). Our results show that insertion of the
hCD2 LCR did not generate gross rearrangement of the vector sequences,
indicating that the hCD2 LCR is stable in the context of an HIV vector.
The introduction of the hCD2 LCR enhanced the T-cell-specific
expression of the transduced gene. Moreover, we show here for the first
time that the hCD2 LCR confers position-independent and copy
number-dependent expression of the transgene in human T cells. These
results demonstrate the potential of using LCRs in combination with
lentivirus vectors to direct stable and high-level expression of
transgenes for the treatment of human diseases. Our results are
consistent with a recent study by May et al. (32), demonstrating that the human
-globin LCR is stable in an HIV vector
and confers increased, long-term
-globin expression in
-thalassemic mice. These results raise hope that the problem of
rearrangements of the vector, as observed in MLV-based vectors, may be
overcome by the use of lentivirus vectors.
 |
MATERIAL AND METHODS |
Plasmid construction.
To generate pHIV (Fig.
1A), the following
fragment was cloned into a pBluescript SK(
) backbone
in the unique NotI and EcoRI sites in the
polylinker: a 1-kb fragment comprising the sequence from nucleotide
position
53 relative to the transcription initiation site to the
PstI site in pv653RSN (41), amplified by PCR
using the two primers 5'-GGCGGAATTCGGAGTGGCGAGCCCTCAGATC-3'
and 5'-CATGCACTGGATGCACTCTATC-3'. The remainder of the
HIV sequence in pHIV is identical to that of pv653RSN except that the
U3 region of the 3' long terminal repeat (LTR) has a 400-bp deletion
that removes all the cis-regulatory elements for
transcription initiation in the HIV U3 region. This deletion was
generated similarly as reported by Zufferey et al. (54),
leading to the production of self-inactivating lentivirus vectors. To
insert the enhancer of the cytomegalovirus (CMV) immediate-early (IE)
gene (2), a 590-bp fragment containing the CMV enhancer was PCR amplified using pCMV-lux (J.-K. Yee, unpublished data) as a
template. The sequences of the two PCR primers used are
5'-ACATATCGATTGGCTCATGTCCAACATTACCG-3' and
5'-GACCGAATTCCGTACACGCCTACCGCCCATT-3'.


View larger version (86K):
[in this window]
[in a new window]
|
FIG. 1.
Structures of HIV vectors. (A) Structure of pHIV. Arrows
represent LTRs; CMV is the enhancer of the CMV IE gene; U3
symbolizes the 400-bp deletion in the 3' LTR; ori represents the SV40
replication origin; RRE is the Rev/Rev-responsive element;
BamHI is the unique cloning site in pHIV. (B) Structures of
pHIV/CK-4 and pHIV/CK-3. LCR represents the 2-kb fragment carrying the
hCD2 LCR; SV40 is the SV40 early promoter. The probes used for Southern
blots and the expected fragment sizes are indicated. (C) Southern blot
analysis of vector integrity in unselected HT1080 cells. HT1080 cells
were transduced with pHIV/CK-3 at high MOI. The genomic DNA was
isolated and cut with XhoI (lane 2) or SacI (lane
3). pHIV/CK-3 was digested with XhoI (lane 1) or
SacI (lane 4) and used as a positive control. Genomic DNA of
untransduced cells was used as a negative control (lane 5). The blot
was hybridized to probe B (Fig. 1 B). The expected fragment sizes were
6.1 and 2.2 kb.
|
|
The PCR product that carried a
ClaI site at the 5' end and
an
EcoRI site at the 3' end was inserted immediately
upstream of
the PCR-amplified 5' LTR fragment described above in order
to
create a CMV-5' LTR fusion. This fusion removed all of the HIV
sequence upstream from the TATA box and replaced it with the CMV
enhancer, rendering the generation of the HIV-1 vector Tat independent
(
26). To increase expression of the genomic RNA of the
vector
in 293T cells, a 200-bp
BamHI/
HindIII
fragment containing the
simian virus 40 (SV40) replication origin was
isolated from pSV2Agpt
(
23) and inserted immediately
upstream of the CMV enhancer.
For the construction of pHIV/CK-3 and
pHIV/CK-4, a 2-kb
ClaI/
SmaI
fragment containing
the hCD2 LCR (
28), a 200-bp
SmaI/
HindIII
fragment containing the SV40
early promoter (
14), and a 3.9-kb
HindIII/
XbaI fragment containing the

-
geo gene (
13) were cloned
into pBluescript
SK(

) to generate pCK-3. A 6.1-kb
XhoI/
NotI
fragment
containing the hCD2 LCR and the

-
geo gene under
the control of
the SV40 promoter was isolated from pCK-3 and inserted
into the
unique
BamHI site in pHIV to generate pHIV/CK-3
(Fig.
1B). A 4.1-kb
SalI/
NotI fragment containing
the

-
geo gene under the control
of the SV40 promoter was
isolated from pCK-3 and inserted into
the unique
BamHI site
in pHIV to generate pHIV/CK-4.
Cell culture.
HT1080 and 293T cells were maintained in
high-glucose (4.5 g/liter) Dulbecco's modified Eagle's medium
supplemented with 10% fetal calf serum, 2 mM L-glutamine,
and 100 mg of gentamicin/liter. Jurkat and primary human T cells were
maintained in RPMI 1640 medium supplemented with 10% fetal calf serum
and 100 mg of gentamicin/liter. Primary human T cells were also
supplemented with 25 U of recombinant human interleukin-2 (rhIL-2;
Chiron, Emeryville, Calif.) per ml. Peripheral blood mononuclear cells
were isolated by a Ficoll gradient and activated by OKT3 (30 ng/ml;
Ortho Biotech, Raritan, N.J.) and (25 U/ml) rhIL-2 for 2 days before
vector transduction.
Vector production and cell transduction.
To produce
infectious vectors, 293T cells were plated at a density of 4 × 106 cells per 10-cm-diameter culture dish. The cells were
cotransfected with 10 µg of pCMV-HIV-1 (16), 10 µg of
pCMV-G (53), and 20 µg of pHIV/CK-3 or pHIV/CK-4 by
calcium phosphate coprecipitation (17). The culture medium
was replaced with fresh medium after 6 h. The supernatant was
collected 16 h after the transfection and stored at
80°C. To
determine the vector titers, 105 HT1080 cells were seeded
in a six-well plate in the presence of 4 µg of Polybrene/ml. The
cells were transduced for 5 h with various dilutions of the
vector. The culture medium was replaced 48 h later with fresh
medium containing G418 at a concentration of 600 µg/ml.
G418-resistant colonies were counted 14 days after transduction. Jurkat
and primary human T cells were similarly transduced with a multiplicity
of infection (MOI) of 10. The concentrations of G418 used for selection
of transduced Jurkat and primary T cells were 600 and 800 µg/ml,
respectively. Primary T cells were cloned and expanded as previously
described (21).
-Gal assay.
Extracts were prepared from exponentially
growing cells in six-well plates. The cells were resuspended in 100 µl of 250 mM Tris-HCl (pH 7.8) and subjected to four freeze-thaw
cycles. Cell debris was removed by centrifugation, and the supernatant
was used for the
-galactosidase (
-Gal) assay. To assay for
-Gal activity, 50-µl aliquots of the extracts were added to 450 µl of
-Gal buffer (0.05 M Tris-HCl) [pH 7.5], 0.1 M NaCl, 0.01 M MgCl2) containing 0.75 mg of
o-nitrophenyl-
-D-galactopyranoside/ml. The
samples were incubated at 37°C for 30 min, and the reaction was
terminated by adding 500 µl of 1 M Na2CO3.
-Gal activity was determined by measuring the optical density at 420 nm with visible light. Units of active
-Gal were determined from a
standard curve of
-Gal activity versus protein concentration, using
purified
-Gal (Sigma, St. Louis, Mo.). The total protein
concentration of the cell extract was determined by the Bradford method
(3).
Southern blot analysis.
Genomic DNA was isolated as
described previously (49). For copy number determination
and integration site analysis, approximately 10 µg of the isolated
DNA was digested with PstI overnight. The DNA fragments were
separated on 1% agarose gels and blotted onto Nytran Supercharge
membranes (Schleicher & Schuell, Dassel, Germany). The DNA probe was
prepared by PCR amplification of a 740-bp fragment immediately upstream
of the Rev/Rev-responsive element sequence in the vector (Fig. 1B,
probe A). The sequences of the primers are
5'-ACCAGAGCTCTCTCGACGCA-3' and
5'-CCATTCTGCAGCTTCCTCAT-3'.
The amplified fragment was labeled with [
32P]dATP by
using a DNA labeling kit from ICN (Costa Mesa, Calif.) and hybridized
with
the membranes. The membranes were washed with 0.1× SSC (1× SSC
is 0.15 M NaCl plus 0.015 M sodium citrate)-0.1% sodium dodecyl
sulfate for 15 min at 65°C three times and subjected to
autoradiography.
To determine provirus integrity, the genomic DNA was
digested
with either
XhoI or
SacI overnight. The
DNA was similarly separated,
transferred, and hybridized to a 470-bp
PCR-amplified probe containing
sequences within the

-
geo
gene (Fig.
1, probe B). The sequences
for the primers are
5'-GAATTCCGCCGATACTGACG-3' and
5'-TTTATCAGCCGGAAAACCTA-3'
 |
RESULTS |
Generation of HIV vectors.
To test hCD2 LCR functions, we
first generated a vector backbone, pHIV (Fig. 1A). This construct
contained the replication origin of SV40 to enhance plasmid replication
in 293T cells. For Tat-independent vector production, most of the U3
region in the 5' LTR of pHIV was replaced with the enhancer of the CMV
IE gene. In addition, the cis-regulatory sequences in the U3
region of the 3' LTR were removed to produce self-inactivating vectors
(54), which minimized the possibility of vector
mobilization by wild-type HIV. A fragment containing the
-geo gene under the control of the SV40 early promoter
and the hCD2 LCR was inserted into pHIV to generate pHIV/CK-3 (Fig.
1B). The presence of the
-geo gene product, a fusion
between neomycin phosphotransferase and
-Gal, allows both the selection of the transduced cells in G418-containing medium and the quantification of gene expression by the
-Gal assay
(13). pHIV/CK-4 lacking the hCD2 LCR was constructed to serve as a control vector. Infectious vectors were generated by transient transfection of the vector construct together with a packaging plasmid and a plasmid containing the vesicular stomatitis virus G gene into 293T cells (16). To determine titers,
human fibrosarcoma HT1080 cells were transduced with the vectors and selected in G418-containing medium. Both vectors gave similar titers
ranging between 3 × 105 and 5 × 105
CFU/ml, which is equivalent to approximately 3,000 transinducing units
of p24/ng. These results suggest that the presence of the hCD2 LCR has
very little effect on vector production.
A previous report indicated that the presence of the hCD2 LCR in MLV
vectors caused frequent rearrangement of the vector genome
(
25). To determine whether a similar event occurred in the
context
of an HIV vector backbone, we transduced HT1080 cells with
pHIV/CK-3
at an MOI of 10 and isolated chromosomal DNA from unselected
cells.
The DNA was digested with either
XhoI or with
SacI and subjected
to Southern blot analysis using probe B
derived from the

-
geo gene (Fig.
1B). As shown in Fig.
1C, the probe detected a 6.1-kb
fragment with
XhoI digestion
and a 2.2-kb fragment with
SacI digestion,
as predicted from
the vector map (Fig.
1B). No other aberrant-size
fragments were
detected. At an MOI of 10, close to 100% of HT1080
cells were expected
to be transduced, given that an MOI of 1 led
to transduction
efficiencies of greater than 95% (data not shown).
Thus, we should
have been able to detect any major rearrangements
in the proviruses.
Since the transduced HT1080 cells were not
preselected for G418
resistance, we concluded that, unlike in
MLV vectors, the presence of
the hCD2 LCR in an HIV vector did
not cause major instability of the
vector
genome.
Lack of hCD2 LCR functions in transduced HT1080 cells.
To
investigate the T-cell specificity of the hCD2 LCR, HT1080 cells were
transduced with either pHIV/CK-3 or pHIV/CK-4. G418-resistant cells
were pooled, and the protein extracts of exponentially growing cells
were prepared and assayed for
-Gal activity. As shown in Fig.
2, no significant differences in the
levels of
-Gal expression were detected in either pHIV/CK-3- or
pHIV/CK-4-transduced cells. To analyze clonal variation of
-Gal
expression, individual G418-resistant clones were isolated from cells
transduced with each vector and tested for
-Gal activity. As shown
in Fig. 3A, the levels of
-Gal
expression varied approximately 33-fold among 18 clones transduced with
pHIV/CK-3. Clones transduced with pHIV/CK-4 showed a 39-fold variation.
Thus, the hCD2 LCR confers no position-independent expression of the
-geo gene in a fibroblast cell line.

View larger version (28K):
[in this window]
[in a new window]
|
FIG. 2.
T-cell-specific stimulation of -Gal expression
mediated by the hCD2 LCR in cell pools. HT1080, Jurkat, and primary
human T cells were transduced with pHIV/CK-3 or with pHIV/CK-4 at an
MOI of 10. Transduced cells were selected with G418. Cell extracts were
prepared by freeze-thaw cycles. -Gal expression in the cell pools
was quantified and corrected for the protein concentration of the
samples. All assays were carried out at least three times with freshly
prepared cell extracts of exponentially growing cells. Standard
deviations are indicated.
|
|

View larger version (16K):
[in this window]
[in a new window]
|
FIG. 3.
T-cell-specific stimulation of -Gal expression
mediated by the hCD2 LCR in individual clones. HT1080 and Jurkat cells
were transduced with pHIV/CK-3 or pHIV/CK-4 at an MOI of 10 (as
determined in HT1080 cells). Transduced cells were selected with 600 µg of G418/ml. Individual clones were isolated after 2 weeks of
selection. The expression of -Gal in individual clones was
quantified and normalized to the protein concentration of the samples.
Three assays were carried out per clone with freshly prepared cell
extracts of exponentially growing cells each time. Each dot represents
the average -Gal activity of three assays. The mean expression
levels of all clones are indicated by horizontal lines. (A) HT1080
clones; (B) Jurkat clones. -Gal expression varied 55-fold among
clones transduced with pHIV/CK-4, while the variation in
pHIV/CK-3-transduced clones was 4-fold (P < 0.001,
Wilcoxon rank sum test). The arrow in panel B indicates the clone
containing two vector copies, as determined by Southern blot analysis
(Fig. 4A, lane 3).
|
|
hCD2 LCR confers position-independent gene expression in T
cells.
To study the functions of hCD2 LCR in T cells, Jurkat cells
were transduced with either of the two vectors at an MOI of 10. G418-resistant cells were pooled, and cell extracts were prepared for
the
-Gal assay. As shown in Fig. 2, the level of
-Gal expression in pHIV/CK-3-transduced Jurkat cells was 3.5-fold higher than that in
pHIV/CK-4-transduced cells, indicating the presence of a
T-cell-specific enhancer in the hCD2 LCR. To study the effect of the
LCR on position-independent gene expression, 18 individual Jurkat
clones derived from the cells transduced with each vector were isolated
and assayed for
-Gal activity. As shown in Fig. 3B, the average
-Gal activity of the 18 clones derived from pHIV/CK-3-transduced cells was threefold higher than that derived from pHIV/CK-4-transduced cells, consistent with the result of the pooled cells shown in Fig. 2.
While the
-Gal activity among the clones derived from pHIV/CK-4-transduced cells varied 55-fold (Fig. 3B), only a 4-fold variation in
-Gal expression was observed among the clones derived from pHIV/CK-3-transduced cells (P < 0.001, Wilcoxon
rank sum test). Since Jurkat cells were transduced with pHIV/CK-3 and
pHIV/CK-4 at the same MOI, a difference in the proviral copy number is
unlikely to account for the variation in
-Gal expression between the
two groups of Jurkat clones. Thus, the presence of the hCD2 LCR in an
HIV vector not only increases gene expression specifically in T cells
but also reduces the influence of the host chromosomal DNA around the
integration site on transgene expression.
To determine the vector copy in each clone and to confirm random vector
integration, chromosomal DNA was isolated from the
pHIV/CK-3-transduced
clones, digested with restriction enzymes,
and subjected to Southern
blot analysis.
PstI digested only once
in the vector, and
the probe used (Fig.
1B, probe A) should hybridize
with DNA fragments
greater than 1 kb, including the vector sequence
and the flanking host
chromosomal DNA. As shown in Fig.
4A, 9
out of 10 randomly picked Jurkat clones derived from the pHIV/CK-3
transduction contained one hybridized fragment, indicating the
presence
of one vector copy. As expected, the vector integrated
randomly since
the sizes of the DNA fragments varied among different
clones. One clone
(Fig.
4A, lane 3) clearly contained two vector
copies. It is
interesting that the

-Gal activity of this particular
clone was
twofold higher than the average activity of all other
clones tested
(Fig.
3B). As demonstrated above,

-Gal activity
varied fourfold
among the pHIV/CK-3-transduced clones. If we normalize

-Gal
expression to vector copy number, this variation is reduced
to only
threefold.

View larger version (66K):
[in this window]
[in a new window]
|
FIG. 4.
Southern blot analysis of vector integration in
individual Jurkat clones. (A) Analysis of vector integration sites and
copy number. All DNA samples were digested with PstI, which
cuts once in the vector sequence. The probe hybridized to the sequence
upstream of the PstI site (Fig. 1B, probe A). (B) Analysis
of provirus integrity. Lanes 1 to 10, individual G418-resistant clones;
lane 11, untransduced Jurkat cells. All DNA samples were digested with
XhoI, which generated a 6.1-kb fragment comprising the hCD2
LCR and the -geo gene. The blot was hybridized to probe B
(Fig. 1B).
|
|
To determine the integrity of the provirus, the DNA from 10 of the
pHIV/CK-3-derived clones was digested with either
XhoI
or
SacI and hybridized with probe B (Fig.
1B).
XhoI
digestion
generates a 6.1-kb fragment containing the entire hCD2 LCR,
the
SV40 promoter, and the

-
geo gene (Fig.
1B, probe B).
As shown
in Fig.
4B, all 10 clones showed the presence of the 6.1-kb
fragment.
As expected,
SacI digestion generated a 2.2-kb
fragment containing
the 3' half of the

-
geo gene and most
of the 3' LTR (data not
shown). These results confirm that no gross
rearrangement occurred
in the integrated vector structure carrying the
hCD2 LCR
sequence.
To determine whether hCD2 LCR can also function in primary cells,
primary human T cells isolated from peripheral blood and
stimulated
with OKT3 and rhIL-2 were transduced with either pHIV/CK-3
or pHIV/CK-4
at an MOI of 10. G418-resistant cells were either
pooled or isolated as
individual clones. As shown in Fig.
2, the
level of

-Gal expression
in the pooled T cells transduced with
pHIV/CK-3 is approximately
threefold higher than that in T cells
transduced with pHIV/CK-4. Thus,
the T-cell-specific enhancer
in hCD2 LCR activates the linked SV40
promoter to similar levels
in both Jurkat cells and primary human T
cells. The

-Gal activities
of individual clones derived from
pHIV/CK-3-transduced primary
human T cells were also determined. As
shown in Fig.
5,

-Gal
activity varied
between three- and fourfold among these clones,
consistent with the
results obtained from pHIV/CK-3-transduced
Jurkat cells. Thus, the hCD2
LCR functions similarly in both a
well-established human T-cell line
and primary human T cells,
conferring position-independent and
T-cell-specific expression
of the linked gene from a heterologous
promoter.

View larger version (9K):
[in this window]
[in a new window]
|
FIG. 5.
LCR-mediated -Gal gene expression in individual
primary T-cell clones. Primary human T cells were transduced with
pHIV/CK-3 at an MOI of 10. Transduced cells were selected with G418.
The -Gal activity in individual clones was quantified and corrected
for the protein concentration in the samples. The average expression
level is indicated by a horizontal line. Each dot represents the
average -Gal activity from three independent assays.
|
|
hCD2 LCR-mediated gene expression is copy number dependent.
To
investigate the effect of multiple LCR copies on the expression level
of
-Gal, one clone carrying one copy of the LCR (as confirmed by
Southern blot analysis) was transduced with pHIV/CK-3 at an MOI of 20. Individual clones were isolated, and the cell extracts were assayed for
-Gal activity. As shown in Fig. 6A, a
distinct pattern of
-Gal expression was revealed: the
-Gal activity of 11 clones was in the same range as that of the parental clone, the
-Gal activity of 5 clones was on average 2.5 times higher
than that of the parental clone, and one clone showed
-Gal activity
3.6 times higher than that of the parental clone (Fig. 6A). The
chromosomal DNA from some clones was isolated, digested with
PstI, and subjected to Southern blotting. As shown in Fig. 6B, the clone showing
-Gal activity 3.6-fold higher than that of the
parental clone contained three vector copies. Five clones with
-Gal
activities about 2.5 times higher than the parental clone carried two
copies, and three clones revealing
-Gal activities in the same range
as the parental clone harbored only one vector copy. The blot also
confirms that the integration of the vector occurred randomly. Since
the level of
-Gal expression is proportional to the vector copy
number in the clones, this result suggests that hCD2 LCR confers copy
number-dependent, integration site-independent expression in the
context of a lentivirus vector.

View larger version (50K):
[in this window]
[in a new window]
|
FIG. 6.
Copy number-dependent -Gal gene expression in Jurkat
cells. (A) -Gal activities of Jurkat clones reinfected with
pHIV/CK-3. A Jurkat clone carrying one copy of pHIV/CK-3 was reinfected
with pHIV/CK-3 at an MOI of 20 to introduce multiple copies of
pHIV/CK-3. -Gal expression of individual clones was measured and
normalized to the total protein concentration. Two assays were carried
out per clone with freshly prepared cell extracts of exponentially
growing cells each time. The results represent the mean -Gal
activity of two assays. The arrow indicates the -Gal activity of the
parental clone; N indicates the -Gal activity in untransduced Jurkat
cells. Clones in groups 1, 2, and 3 contain one, two, and three
proviral vector copies, respectively, as determined by Southern blot
analysis (B). (B) Southern blot analysis of the vector copy number in
reinfected Jurkat cell clones. The genomic DNA from clones in groups 1, 2, and 3 (A) was digested with PstI, which cuts once in the
vector sequence. The blot was hybridized to probe A (Fig. 1B).
|
|
 |
DISCUSSION |
For successful gene therapy approaches in the treatment of human
diseases, the therapeutic gene must be delivered efficiently and
expressed in a tissue-specific and constant level over time. MLV
vectors have been widely used to deliver genes into mammalian cells.
Since these vectors integrate randomly into host genome, the gene
expression is strongly influenced by the surrounding chromatin, leading
to position effect variegation and gene silencing either upon
integration or following cell expansion (48). These problems were expected to be overcome with the discovery of the LCRs,
given that LCRs confer tissue-specific, high-level, and integration-site independent expression of the transgene in cell lines
as well as in transgenic mice (18, 28, 37). However, the
introduction of the
-globin LCR or the hCD2 LCR into MLV vectors led
invariably to rearrangements of the vector sequence and low vector
titers (39). Combining LCR fragments with only the
nuclease hypersensitivity sites or reversing the orientation of the LCR
alleviated the problem of vector instabilities and increased vector
titers, but transgene expression remained integration site dependent
(7, 25, 29, 31, 48).
Unlike MLV vectors, HIV vectors are capable of transducing nondividing
cells in culture and in vivo (4-6, 8, 15, 24, 30, 35, 38,
47). The significant divergence of the HIV sequence from the MLV
sequence and the stability of some cis-regulatory elements
in the context of lentivirus vectors prompted us to test the stability
and function of the hCD2 LCR in an HIV vector. Southern blot analysis
from pooled cells demonstrated no gross rearrangement of the proviral
structure, suggesting that the hCD2 LCR is more stable in the context
of an HIV vector than in an MLV vector. The hCD2 LCR did not stimulate
the SV40 promoter in HT1080 cells. In Jurkat and primary human T cells,
the SV40 promoter was stimulated in the presence of the LCR,
demonstrating T-cell-specific enhancer activity of the hCD2 LCR in the
context of a lentivirus vector. This is in direct contrast with the
results reported by Kaptein et al. (25), showing no hCD2
LCR function in the context of an MLV vector. The latter study and our
present study used exactly the same LCR fragment, which suggests that
sequences in the MLV vector act negatively to suppress the hCD2 LCR
function. This is consistent with the observation by McCune and Townes
that MLV sequences down-regulated the
-globin LCR function in
transgenic mice (33). Removal of the MLV enhancer and
promoter from the retrovirus vector proved to be nonessential for the
repression of
-globin expression in McCune and Towne's study
(33). This observation rules out the possibility that
promoter interference could be responsible for the repression. This
suggests that the lack of an active HIV promoter in our vector did not
account for the differences between our results and those of Kaptein et
al. (25).
Stimulation of SV40 promoter activity by the hCD2 LCR enhancer,
however, is relatively modest, ranging between three- and fourfold.
This is in contrast to the study of Lake et al., demonstrating that the
enhancer in hCD2 LCR stimulated a linked thymidine kinase promoter of
herpes simplex virus to much higher levels in a transient transfection
assay (27). The variation in promoter stimulation may be
explained by the different approaches used to assay for enhancer
activity, one by transient transfection and the other by stable
integration. But it is also likely that the heterologous promoters used
for the enhancer assay may interact with the LCR with different
efficiencies. To achieve efficient and tissue-specific gene expression
with the hCD2 LCR in vivo, it may be necessary to combine the authentic
hCD2 promoter together with its LCR to direct gene expression in an HIV
vector. In a previous study, a significant increase in gene expression
levels could be obtained when the
-globin LCR was combined with its
own promoter in an MLV-based vector to drive
-globin gene expression
(31).
Analysis of individual Jurkat clones demonstrated that the clonal
variation of
-geo gene expression among
pHIV/CK-3-transduced cells is significantly lower than that among
pHIV/CK-4-transduced cells. The variation in
-geo
expression is most likely underestimated in our study because the
Jurkat clones were preselected for G418 resistance. Only those clones
containing the vector integrated into favored chromosomal sites would
express sufficient amounts of the
-geo gene and survive
the selection. Thus, the position effect on gene expression among
pHIV/CK-4-transduced Jurkat cells may even be larger than the observed
55-fold. This variation in expression levels is consistent with results
obtained for MLV vectors containing no LCR (25). On the
other hand, the
-Gal expression levels in pHIV/CK-3-transduced
Jurkat clones containing the LCR fell in a narrow range. The pHIV/CK-3
Jurkat clone expressing the highest
-Gal level contains two
integrated HIV vectors. If the
-Gal activity of this clone is
normalized to the vector copy number, the level of
-Gal expression
falls within the average range of other pHIV/CK-3 transduced clones.
These results strongly suggest that the hCD2 LCR confers
position-independent expression of the gene inserted into an HIV vector.
Results of reintroduction of the vector into an already transduced
Jurkat clone confirmed copy number-dependent gene expression conferred
by the hCD2 LCR. Thus, the hCD2 LCR, when placed in the context of an
HIV vector backbone, directs tissue-specific, integration
site-independent and copy number-dependent expression of the gene from
a heterologous promoter. Similar results were obtained with primary
human T cells, suggesting that the effect of the LCR is not limited to
established cell lines.
Whether the LCR function can persist upon gene delivery into HSC and
subsequent differentiation of the transduced stem cells into T cells in
vivo remains to be tested. But the recent observation by May et al.
(32) that the silencing of gene expression occurred less
frequently from lentivirus vectors than from oncoretrovirus vectors
raises hope that the LCR function can indeed persist in vivo over time.
The study by May et al. demonstrates that the insertion of a large
fragment of the
-globin LCR into an HIV vector, followed by mouse
HSC transduction, led to long-term, therapeutic levels of
-globin
expression in
-thalassemic mice.
 |
ACKNOWLEDGMENTS |
This work was supported by NIH grant AI46030.
We thank J. Sodroski for kindly providing plasmid pv653RSN and D. Kioussis for the hCD2 LCR fragment. We also thank M. Jensen for the
isolation of PBMC and for helpful advice.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: City of Hope,
Miller Bldg., #110, 1500 E. Duarte Rd., Duarte, CA 91010. Phone: (626) 359-4111, ext. 8807. Fax: (626) 301-8280. E-mail:
jyee{at}coh.org.
 |
REFERENCES |
| 1.
|
Bonifer, C.,
M. Vidal,
F. Grosveld, and A. E. Sippel.
1990.
Tissue specific and position independent expression of the complete gene domain for chicken lysozyme in transgenic mice.
EMBO J.
9:2843-2848[Medline].
|
| 2.
|
Boshart, M.,
F. Weber,
G. Jahn,
K. Dorsch-Hasler,
B. Fleckenstein, and W. Schaffner.
1985.
A very strong enhancer is located upstream of an immediate early gene of human cytomegalovirus.
Cell
41:521-530[CrossRef][Medline].
|
| 3.
|
Bradford, M. M.
1976.
A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding.
Anal. Biochem.
72:248-254[CrossRef][Medline].
|
| 4.
|
Buchschacher, G. L., Jr., and F. Wong-Staal.
2000.
Development of lentiviral vectors for gene therapy for human diseases.
Blood
95:2499-2504[Abstract/Free Full Text].
|
| 5.
|
Bukrinsky, M. I.,
S. Haggerty,
M. P. Dempsey,
N. Sharova,
A. Adzhubel,
L. Spitz,
P. Lewis,
D. Goldfarb,
M. Emerman, and M. Stevenson.
1993.
A nuclear localization signal within HIV-1 matrix protein that governs infection of non-dividing cells.
Nature
365:666-669[CrossRef][Medline].
|
| 6.
|
Case, S. S.,
M. A. Price,
C. T. Jordan,
X. J. Yu,
L. Wang,
G. Bauer,
D. L. Haas,
D. Xu,
R. Stripecke,
L. Naldini,
D. B. Kohn, and G. M. Crooks.
1999.
Stable transduction of quiescent CD34(+)CD38( ) human hematopoietic cells by HIV-1-based lentiviral vectors.
Proc. Natl. Acad. Sci. USA
96:2988-2993[Abstract/Free Full Text].
|
| 7.
|
Chang, J. C.,
D. Liu, and Y. W. Kan.
1992.
A 36-base-pair core sequence of locus control region enhances retrovirally transferred human beta-globin gene expression.
Proc. Natl. Acad. Sci. USA
89:3107-3110[Abstract/Free Full Text].
|
| 8.
|
Curran, M. A.,
S. M. Kaiser,
P. L. Achacoso, and G. P. Nolan.
2000.
Efficient transduction of nondividing cells by optimized feline immunodeficiency virus vectors.
Mol. Ther.
1:31-38[CrossRef][Medline].
|
| 9.
|
Diaz, P.,
D. Cado, and A. Winoto.
1994.
A locus control region in the T cell receptor alpha/delta locus.
Immunity
1:207-217[CrossRef][Medline].
|
| 10.
|
Festenstein, R.,
M. Tolaini,
P. Corbella,
C. Mamalaki,
J. Parrington,
M. Fox,
A. Miliou,
M. Jones, and D. Kioussis.
1996.
Locus control region function and heterochromatin-induced position effect variegation.
Science
271:1123-1125[Abstract].
|
| 11.
|
Flanagan, J. R.,
K. G. Becker,
D. L. Ennist,
S. L. Gleason,
P. H. Driggers,
B. Z. Levi,
E. Appella, and K. Ozato.
1992.
Cloning of a negative transcription factor that binds to the upstream conserved region of Moloney murine leukemia virus.
Mol. Cell. Biol.
12:38-44[Abstract/Free Full Text].
|
| 12.
|
Friedmann, T.
1989.
Progress toward human gene therapy.
Science
244:1275-1281[Abstract/Free Full Text].
|
| 13.
|
Friedrich, G., and P. Soriano.
1991.
Promoter traps in embryonic stem cells: a genetic screen to identify and mutate developmental genes in mice.
Genes Dev.
5:1513-1523[Abstract/Free Full Text].
|
| 14.
|
Fromm, M., and P. Berg.
1983.
Transcription in vivo from SV40 early promoter deletion mutants without repression by large T antigen.
J. Mol. Appl. Genet.
2:127-135[Medline].
|
| 15.
|
Gallay, P.,
T. Hope,
D. Chin, and D. Trono.
1997.
HIV-1 infection of nondividing cells through the recognition of integrase by the importin/karyopherin pathway.
Proc. Natl. Acad. Sci. USA
94:9825-9830[Abstract/Free Full Text].
|
| 16.
|
Gasmi, M.,
J. Glynn,
M. J. Jin,
D. J. Jolly,
J. K. Yee, and S. T. Chen.
1999.
Requirements for efficient production and transduction of human immunodeficiency virus type 1-based vectors.
J. Virol.
73:1828-1834[Abstract/Free Full Text].
|
| 17.
|
Graham, F. L., and A. J. van der Eb.
1973.
A new technique for the assay of infectivity of human adenovirus 5 DNA.
Virology
52:456-467[CrossRef][Medline].
|
| 18.
|
Greaves, D. R.,
F. D. Wilson,
G. Lang, and D. Kioussis.
1989.
Human CD2 3'-flanking sequences confer high-level, T cell-specific, position-independent gene expression in transgenic mice.
Cell
56:979-986[CrossRef][Medline].
|
| 19.
|
Grosveld, F.,
G. B. van Assendelft,
D. R. Greaves, and G. Kollias.
1987.
Position-independent, high-level expression of the human beta-globin gene in transgenic mice.
Cell
51:975-985[CrossRef][Medline].
|
| 20.
|
Hoeben, R. C.,
A. A. Migchielsen,
R. C. van der Jagt,
H. van Ormondt, and A. J. van der Eb.
1991.
Inactivation of the Moloney murine leukemia virus long terminal repeat in murine fibroblast cell lines is associated with methylation and dependent on its chromosomal position.
J. Virol.
65:904-912[Abstract/Free Full Text].
|
| 21.
|
Jensen, M. C.,
P. Clarke,
G. Tan,
C. Wright,
W. Chung-Chang,
T. N. Clark,
F. Zhang,
M. L. Slovak,
A. M. Wu,
S. J. Forman, and A. Raubitschek.
2000.
Human T lymphocyte genetic modification with naked DNA.
Mol. Ther.
1:49-55[CrossRef][Medline].
|
| 22.
|
Jones, B. K.,
B. R. Monks,
S. A. Liebhaber, and N. E. Cooke.
1995.
The human growth hormone gene is regulated by a multicomponent locus control region.
Mol. Cell. Biol.
15:7010-7021[Abstract].
|
| 23.
|
Kadesch, T., and P. Berg.
1986.
Effects of the position of the simian virus 40 enhancer on expression of multiple transcription units in a single plasmid.
Mol. Cell. Biol.
6:2593-2601[Abstract/Free Full Text].
|
| 24.
|
Kafri, T.,
U. Blomer,
D. A. Peterson,
F. H. Gage, and I. M. Verma.
1997.
Sustained expression of genes delivered directly into liver and muscle by lentiviral vectors.
Nat. Genet.
17:314-317[Medline].
|
| 25.
|
Kaptein, L. C.,
M. Breuer,
D. Valerio, and V. W. van Beusechem.
1998.
Expression pattern of CD2 locus control region containing retroviral vectors in hemopoietic cells in vitro and in vivo.
Gene Ther.
5:320-330[CrossRef][Medline].
|
| 26.
|
Kim, V. N.,
K. Mitrophanous,
S. M. Kingsman, and A. J. Kingsman.
1998.
Minimal requirement for a lentivirus vector based on human immunodeficiency virus type 1.
J. Virol.
72:811-816[Abstract/Free Full Text].
|
| 27.
|
Lake, R. A.,
D. Wotton, and M. J. Owen.
1990.
A 3' transcriptional enhancer regulates tissue-specific expression of the human CD2 gene.
EMBO J.
9:3129-3136[Medline].
|
| 28.
|
Lang, G.,
C. Mamalaki,
D. Greenberg,
N. Yannoutsos, and D. Kioussis.
1991.
Deletion analysis of the human CD2 gene locus control region in transgenic mice.
Nucleic Acids Res.
19:5851-5856[Abstract/Free Full Text].
|
| 29.
|
Leboulch, P.,
G. M. Huang,
R. K. Humphries,
Y. H. Oh,
C. J. Eaves,
D. Y. Tuan, and I. M. London.
1994.
Mutagenesis of retroviral vectors transducing human beta-globin gene and beta-globin locus control region derivatives results in stable transmission of an active transcriptional structure.
EMBO J.
13:3065-3076[Medline].
|
| 30.
|
Lewis, P. F., and M. Emerman.
1994.
Passage through mitosis is required for oncoretroviruses but not for the human immunodeficiency virus.
J. Virol.
68:510-516[Abstract/Free Full Text].
|
| 31.
|
Li, Q.,
D. W. Emery,
M. Fernandez,
H. Han, and G. Stamatoyannopoulos.
1999.
Development of viral vectors for gene therapy of beta-chain hemoglobinopathies: optimization of a gamma-globin gene expression cassette.
Blood
93:2208-2216[Abstract/Free Full Text].
|
| 32.
|
May, C.,
S. Rivella,
J. Callegari,
G. Heller,
K. M. Gaensler,
L. Luzzatto, and M. Sadelain.
2000.
Therapeutic haemoglobin synthesis in beta-thalassaemic mice expressing lentivirus-encoded human beta-globin.
Nature
406:82-86[CrossRef][Medline].
|
| 33.
|
McCune, S. L., and T. M. Townes.
1994.
Retroviral vector sequences inhibit human beta-globin gene expression in transgenic mice.
Nucleic Acids Res.
22:4477-4481[Abstract/Free Full Text].
|
| 34.
|
Miller, A. D.
1992.
Retroviral vectors.
Curr. Top. Microbiol. Immunol.
158:1-24[Medline].
|
| 35.
|
Miyoshi, H.,
U. Blomer,
M. Takahashi,
F. H. Gage, and I. M. Verma.
1998.
Development of a self-inactivating lentivirus vector.
J. Virol.
72:8150-8157[Abstract/Free Full Text].
|
| 36.
|
Miyoshi, H.,
M. Takahashi,
F. H. Gage, and I. M. Verma.
1997.
Stable and efficient gene transfer into the retina using an HIV-based lentiviral vector.
Proc. Natl. Acad. Sci. USA
94:10319-10323[Abstract/Free Full Text].
|
| 37.
|
Moon, A. M., and T. J. Ley.
1991.
Functional properties of the beta-globin locus control region in K562 erythroleukemia cells.
Blood
77:2272-2284[Abstract/Free Full Text].
|
| 38.
|
Naldini, L.,
U. Blomer,
P. Gallay,
D. Ory,
R. Mulligan,
F. H. Gage,
I. M. Verma, and D. Trono.
1996.
In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector.
Science
272:263-267[Abstract].
|
| 39.
|
Novak, U.,
E. A. Harris,
W. Forrester,
M. Groudine, and R. Gelinas.
1990.
High-level beta-globin expression after retroviral transfer of locus activation region-containing human beta-globin gene derivatives into murine erythroleukemia cells.
Proc. Natl. Acad. Sci. USA
87:3386-3390[Abstract/Free Full Text].
|
| 40.
|
Palmer, T. D.,
G. J. Rosman,
W. R. Osborne, and A. D. Miller.
1991.
Genetically modified skin fibroblasts persist long after transplantation but gradually inactivate introduced genes.
Proc. Natl. Acad. Sci. USA
88:1330-1334[Abstract/Free Full Text].
|
| 41.
|
Parolin, C.,
T. Dorfman,
G. Palu,
H. Gottlinger, and J. Sodroski.
1994.
Analysis in human immunodeficiency virus type 1 vectors of cis-acting sequences that affect gene transfer into human lymphocytes.
J. Virol.
68:3888-3895[Abstract/Free Full Text].
|
| 42.
|
Plavec, I.,
T. Papayannopoulou,
C. Maury, and F. Meyer.
1993.
A human beta-globin gene fused to the human beta-globin locus control region is expressed at high levels in erythroid cells of mice engrafted with retrovirus-transduced hematopoietic stem cells.
Blood
81:1384-1392[Abstract/Free Full Text].
|
| 43.
|
Raftopoulos, H.,
M. Ward,
P. Leboulch, and A. Bank.
1997.
Long-term transfer and expression of the human beta-globin gene in a mouse transplant model.
Blood
90:3414-3422[Abstract/Free Full Text].
|
| 44.
|
Reitman, M.,
E. Lee,
H. Westphal, and G. Felsenfeld.
1990.
Site-independent expression of the chicken beta A-globin gene in transgenic mice.
Nature
348:749-752[CrossRef][Medline].
|
| 45.
|
Rivella, S., and M. Sadelain.
1998.
Genetic treatment of severe hemoglobinopathies: the combat against transgene variegation and transgene silencing.
Semin. Hematol.
35:112-125[Medline].
|
| 46.
|
Ryan, T. M.,
R. R. Behringer,
N. C. Martin,
T. M. Townes,
R. D. Palmiter, and R. L. Brinster.
1989.
A single erythroid-specific DNase I super-hypersensitive site activates high levels of human beta-globin gene expression in transgenic mice.
Genes Dev.
3:314-323[Abstract/Free Full Text].
|
| 47.
|
Sadaie, M. R.,
M. Zamani,
S. Whang,
N. Sistron, and S. K. Arya.
1998.
Towards developing HIV-2 lentivirus-based retroviral vectors for gene therapy: dual gene expression in the context of HIV-2 LTR and Tat.
J. Med. Virol.
54:118-128[CrossRef][Medline].
|
| 48.
|
Sadelain, M.,
C. H. Wang,
M. Antoniou,
F. Grosveld, and R. C. Mulligan.
1995.
Generation of a high-titer retroviral vector capable of expressing high levels of the human beta-globin gene.
Proc. Natl. Acad. Sci. USA
92:6728-6732[Abstract/Free Full Text].
|
| 49.
|
Sambrook, J.,
E. F. Fritsch, and T. Maniatis.
1989.
Molecular cloning: a laboratory manual, 2nd ed.
Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y.
|
| 50.
|
Speck, N. A., and D. Baltimore.
1987.
Six distinct nuclear factors interact with the 75-base-pair repeat of the Moloney murine leukemia virus enhancer.
Mol. Cell. Biol.
7:1101-1110[Abstract/Free Full Text].
|
| 51.
|
Williams, D. A.,
S. H. Orkin, and R. C. Mulligan.
1986.
Retrovirus-mediated transfer of human adenosine deaminase gene sequences into cells in culture and into murine hematopoietic cells in vivo.
Proc. Natl. Acad. Sci. USA
83:2566-2570[Abstract/Free Full Text].
|
| 52.
|
Xu, L.,
J. K. Yee,
J. A. Wolff, and T. Friedmann.
1989.
Factors affecting long-term stability of Moloney murine leukemia virus-based vectors.
Virology
171:331-341[CrossRef][Medline].
|
| 53.
|
Yee, J. K.,
A. Miyanohara,
P. LaPorte,
K. Bouic,
J. C. Burns, and T. Friedmann.
1994.
A general method for the generation of high-titer, pantropic retroviral vectors: highly efficient infection of primary hepatocytes.
Proc. Natl. Acad. Sci. USA
91:9564-9568[Abstract/Free Full Text].
|
| 54.
|
Zufferey, R.,
T. Dull,
R. J. Mandel,
A. Bukovsky,
D. Quiroz,
L. Naldini, and D. Trono.
1998.
Self-inactivating lentivirus vector for safe and efficient in vivo gene delivery.
J. Virol.
72:9873-9880[Abstract/Free Full Text].
|
Journal of Virology, May 2001, p. 4641-4648, Vol. 75, No. 10
0022-538X/01/$04.00+0 DOI: 10.1128/JVI.75.10.4641-4648.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Hendrickson, B., Senadheera, D., Mishra, S., Bui, K. C. T., Wang, X., Chan, B., Petersen, D., Pepper, K., Lutzko, C.
(2007). Development of Lentiviral Vectors with Regulated Respiratory Epithelial Expression In Vivo. Am. J. Respir. Cell Mol. Bio.
37: 414-423
[Abstract]
[Full Text]
-
Lutzko, C., Senadheera, D., Skelton, D., Petersen, D., Kohn, D. B.
(2003). Lentivirus Vectors Incorporating the Immunoglobulin Heavy Chain Enhancer and Matrix Attachment Regions Provide Position-Independent Expression in B Lymphocytes. J. Virol.
77: 7341-7351
[Abstract]
[Full Text]